Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Crinetics Pharmaceuticals (CRNX)
NASDAQ:CRNX
RESEARCH TOOLSreports
Holding CRNX?
Track your performance easily
CRNX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$35.24 - $62.53
Previous CloseN/A
Volume214.21K
Average Volume (3M)915.37K
Market Cap
$3.30B
Enterprise Value$3.28B
Total Cash (Recent Filing)$12.15M
Total Debt (Recent Filing)$163.00K
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Mar 18, 2025EPS Estimate
-0.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.72
Shares Outstanding92,737,625
10 Day Avg. Volume1,313,297
30 Day Avg. Volume915,372
Standard Deviation0.15
R-Squared0.04
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3278.40
Price to Cash Flow (P/CF)-13.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue3.16K
Enterprise Value/Gross Profit817.97
Enterprise Value/Ebitda-11.68
Forecast
1Y Price Target
$75.75Price Target Upside107.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Crinetics Pharmaceuticals News
PremiumCompany Announcements
Crinetics Pharmaceuticals Outlines 2025 Strategic Priorities
PremiumCompany Announcements
Crinetics Pharmaceuticals Advances Atumelnant After Successful Phase 2
PremiumCompany Announcements
Crinetics Pharmaceuticals Strengthens Leadership with New Appointment
Bulls Say, Bears Say
Bulls Say
Clinical DataAtumelnant was generally well tolerated with no treatment-related severe or serious adverse events, and all participants completed the 12-week treatment period.
Clinical EfficacySubstantial reductions of 60-80% in the primary hormone involved in CAH disease, serum androstenedione (A4), were seen across all 3 dose cohorts, indicating strong treatment efficacy.
Phase AdvancementBased on the positive Phase 2 readout, Crinetics plans to initiate a Phase 3 pivotal trial in the adult CAH population and also start a Phase 2b/3 pivotal trial in the pediatric CAH population.
Bears Say
Financial PerformanceR&D expense and SG&A expense was $88M in 3Q24, a 48% increase YoY, driven by personnel costs and manufacturing/development activities.
Investor ExpectationsThe stock is expensive with high expectations, and data had to be pristine for the stock to trade up.
Safety ConcernsThe stock is down due to safety questions (two cases of liver function test/LFT elevations) and the magnitude of A4 reduction being less robust than the initial Phase 2 results.
---
Ownership Overview
1.76% Insiders
33.10% Mutual Funds
0.10% Other Institutional Investors
50.79% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRNX FAQ
What was Crinetics Pharmaceuticals’s price range in the past 12 months?
Crinetics Pharmaceuticals lowest stock price was $35.24 and its highest was $62.53 in the past 12 months.
What is Crinetics Pharmaceuticals’s market cap?
Crinetics Pharmaceuticals’s market cap is $3.30B.
When is Crinetics Pharmaceuticals’s upcoming earnings report date?
Crinetics Pharmaceuticals’s upcoming earnings report date is Mar 18, 2025 which is in 59 days.
How were Crinetics Pharmaceuticals’s earnings last quarter?
Crinetics Pharmaceuticals released its earnings results on Nov 12, 2024. The company reported -$0.96 earnings per share for the quarter, missing the consensus estimate of -$0.911 by -$0.049.
Is Crinetics Pharmaceuticals overvalued?
According to Wall Street analysts Crinetics Pharmaceuticals’s price is currently Undervalued.
Does Crinetics Pharmaceuticals pay dividends?
Crinetics Pharmaceuticals does not currently pay dividends.
What is Crinetics Pharmaceuticals’s EPS estimate?
Crinetics Pharmaceuticals’s EPS estimate is -0.89.
How many shares outstanding does Crinetics Pharmaceuticals have?
Crinetics Pharmaceuticals has 92,737,625 shares outstanding.
What happened to Crinetics Pharmaceuticals’s price movement after its last earnings report?
Crinetics Pharmaceuticals reported an EPS of -$0.96 in its last earnings report, missing expectations of -$0.911. Following the earnings report the stock price went up 0.238%.
Which hedge fund is a major shareholder of Crinetics Pharmaceuticals?
Among the largest hedge funds holding Crinetics Pharmaceuticals’s share is Driehaus Capital Management LLC. It holds Crinetics Pharmaceuticals’s shares valued at 301M.
---
Crinetics Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$75.75 (107.65% Upside)
$75.75 (107.65% Upside)
Blogger Sentiment
Bullish
CRNX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 279.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.19%
12-Months-Change
Fundamentals
Return on Equity
-40.26%
Trailing 12-Months
Asset Growth
46.11%
Trailing 12-Months
Company Description
Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. It is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.
---
CRNX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented several positive developments including the NDA submission for paltusotine, a strong financial position post-equity offering, and advancements in their drug pipeline and global expansion. However, the financial results showed increased expenses and a higher net loss with no current revenue. Despite these financial challenges, the strategic advancements and promising pipeline provide an optimistic outlook.Read More>---
CRNX Stock 12 Month Forecast
Average Price Target
$75.75
▲(107.65% Upside)
Technical Analysis
Arcutis Biotherapeutics
―
Blueprint Medicines
―
Ultragenyx Pharmaceutical
―
Fate Therapeutics
―
Seres Therapeutics
―
Xencor
―
Best Analysts Covering CRNX
1 Year
1 Year Success Rate
7/13 ratings generated profit
1 Year Average Return
+62.55%
reiterated a buy rating 2 months ago
Copying Brian Skorney's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of +62.55% per trade.
---